5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Product (Pen Injectors, Autoinjectors, Wearable Injectors, Needle-Free Injectors), by Usage, by Application, and by Geography.
Fastest Growing Market:
Self-Injection devices allow patients with chronic diseases to gain control of their treatment schedule and their treatment setting, thus allowing greater independence and freedom in their social, domestic and professional lives. Self-injection may also offer psychological benefits over administration by healthcare professionals, including improved self-esteem. Removing the need to attend a clinic or hospital for regular injections also brings economic benefits to both the patient and the healthcare system. This economic benefit has been the major growth driving factor for this market. Increasing prevalence of chronic autoimmune diseases like rheumatoid arthritis and cancer have also helped the growth as self-injections have application in recovery from these illnesses.
However, stringent regulations for approval from regulatory authorities and lack of awareness of such devices in developing and underdeveloped economies have been restraining the growth of this market.
Self-Injection Devices are injections or wearable devices that can be used by the patient in home setting to administer the medication himself. The market is segmented by product usage, application, and geography.
|Auto Immune Diseases|
Report scope can be customized per your requirements. Click here.
Pen injectors are used for the subcutaneous delivery of biopharmaceuticals. Although they are also administered by professionals, these are primarily used for self-administration by the patient. First developed to replace vials and syringes for the treatment of diabetes with insulin, such injection devices have been an important part of the drug-delivery devices for a long time.
According to 2018 World Health Organization report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This has attributed to rise in global prevalence of diabetes from 4.7% in 1980 to 8.5% in 2014. Moreover, diabetes prevalence has been rising more rapidly in middle- and low-income countries. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Hence, the worldwide increase in diabetes and the growing pressure on health care costs that pushes toward patient self-injection means that their importance is expected to grow further in the future.
To understand key trends, Download Sample Report
According to the Center for Disease control and prevention (CDC), in 2016, there were an estimated 15.5 million cancer survivors in the United States and this number is expected to increase to 20.3 million by 2026. According to article by Ji Lin et al. published in Population Health Metrics Journal 2018, the projected number and percent of adults with diagnosed diabetes would increase from 22.3 million (9.1%) in 2014 to 39.7 million (13.9%) in 2030, and to 60.6 million (17.9%) in 2060. Also, the number of people with diabetes aged 65 years or older expected to increase from 9.2 million in 2014 to 21.0 million in 2030, and to 35.2 million in 2060. Hence, with increasing prevalence of chronic diseases, the demand for self-injection devices, which are used for treatment or recovery from such diseases, are expected to increase.
To understand geography trends, Download Sample Report.
Majority of the key player involved in research and manufacturing of self-injection devices are established in developed countries. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rising awareness.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden Of Chronic Diseases
4.2.2 Benefits And Convenience Leading To Increased Demand For Self Injectors
4.3 Market Restraints
4.3.1 Stringent Regulations for Approval
4.3.2 Growing Use Of Alternative Delivery Methods
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 Pen Injectors
5.1.3 Wearable Injectors
5.1.4 Needle-Free Injectors
5.2 By Usage
5.3 By Application
5.3.2 Auto Immune Diseases
5.3.3 Hormonal Disorders
5.3.4 Pain Management
5.4.1 North America
188.8.131.52 United States
184.108.40.206 Rest of Europe
5.4.3 Asia Pacific
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 Gerresheimer AG
6.1.3 Insulet Corporation
6.1.4 Ypsomed AG
6.1.5 Antares Pharma Inc
6.1.6 West Pharmaceutical Services
6.1.7 Consort Medical plc
6.1.8 Owen Mumford Ltd.
6.1.9 SHL Group Auto
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments